$1,175,000 Debt Conversion by NuOncology Labs.Health & Medical Writers VIRGINIA BEACH Virginia Beach, resort city (1990 pop. 393,069), independent and in no county, SE Va., on the Atlantic coast; inc. 1906. In 1963, Princess Anne co. and the former small town of Virginia Beach were merged, giving the present city an area of 302 sq mi (782 sq km). , Va.--(BW HealthWire)--July 21,2000 NuOncology Labs Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: NLAB), announced today that on June 30, 2000, its founders and largest investor collectively agreed to convert $1,175,000 in loans they have made to NuOncology Labs (NuLab) for shares of NuLab common stock at $0.30 per share. The conversion agreement was formally ratified at the board of directors meeting, July 17th. The stock, which trades on the OTC Pink Sheets, has recently traded between $0.20 and $0.55. Chairman Philip F. Enlow; CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Robert S Robert, Henry Martyn 1837-1923. American army engineer and parliamentary authority. He designed the defenses for Washington, D.C., during the Civil War and later wrote Robert's Rules of Order (1876). Noun 1. . Thomas; Sr. Vice President Research & Laboratory Operations Fraser L. Baker, PhD; and Medical Director R. Michael Williams Michael Williams may refer to:
Coleraine Holdings, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control converted $887,108. Coleraine previously converted $490,000 in NuLab debt at $7.00 per share (May 31, 1999) and $175,000 of debt at $1.75 per share (October 31, 1999). After this conversion of debt, Coleraine Holdings, LLC, will have made equity investments in of approximately $1,600,000 in the company. $23,010 was converted in lieu of fees for previous work by corporate counsel and a consultant. NuOncology Labs engages in research, development, testing and licensing of promising cancer treatments. In its clinical laboratory business, the Company conducts predictive drug response tests for the optimization of chemotherapeutic cancer treatment. Note: Statements in this document that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the early state of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion